

What Are the Real-World Antifibrotic Utilization Rates and Factors Associated With Uptake in Idiopathic Pulmonary Fibrosis?

STUDY DESIGN

Retrospective review of Veterans Affairs (VA) Healthcare System databases identifying patients with idiopathic pulmonary fibrosis (IPF) who had filled a prescription for either nintedanib or pirfenidone between 10/2014 and 12/2019

RESULTS



Among 14,792 veterans with IPF, **17% received antifibrotics**



Index IPF **diagnoses outside the VA were less likely to receive antifibrotic therapy** (adjOR 0.15; 95% CI, 0.10-0.22)



Disparities according to race, sex, and rurality noted with antifibrotic uptake

Factor	adjOR (95% CI)
Female sex	0.41 (0.27-0.63)
Black race	0.60 (0.50-0.74)
Rural residence	0.88 (0.80-0.97)

Uptake of antifibrotic medications among veterans with IPF was low, and there were significant disparities in use related to female sex, Black race, rural residence, and IPF diagnosis outside the VA.